Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chimu Fuyanning is a Traditional Chinese Medicine (TCM) capsule developed by Wuhan Pharmaceutical Valley Technology Development Co., Ltd. for the treatment of sequelae of pelvic inflammatory disease (SPID). The formulation is specifically indicated for patients presenting with the damp-heat and blood stasis syndrome (湿热瘀阻证), a common TCM diagnosis for chronic pelvic inflammation. It functions by clearing heat, resolving dampness, and activating blood circulation to alleviate pain and inflammation. The drug has been evaluated in multi-center, randomized, double-blind, placebo-controlled clinical trials in China (e.g., CTR20132127) to establish its safety and efficacy, as well as to explore optimal clinical dosing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chimu fuyanning.